Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06490367 · ClinicalTrials.gov registry record · NA
Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study
A NA study of Huntington Disease, sponsored by Oregon Health and Science University.
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT06490367: Completed NA study of Huntington Disease, sponsored by Oregon Health and Science University.
NCT06490367 is a NA study of Huntington Disease that has completed, run by Oregon Health and Science University. The registered enrollment target is 22 participants, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06490367, a NA study of Huntington Disease, has completed, sponsored by Oregon Health and Science University.
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial examines whether 12 weeks of time-restricted eating (TRE), otherwise known as intermittent fasting, appears safe and feasible in persons with early-stage Huntington's disease (HD). The study also explores the effects of TRE on biomarkers and clinical measures associated with HD progression.
Primary Outcome
Adherence, measured as the number of days participants can successfully limit the eating window to 6-8 hours as tracked through self-reported surveys and time-stamped meal logs, is calculated for each participant during the 12 weeks of TRE.
Conditions Studied
Interventions
- BEHAVIORAL Time-Restricted Eating Diet
Study Locations (1)
Oregon
- Oregon Health and Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2024-08-29 |
| Est. Completion | 2025-05-30 |
| Phase | NA |
What the finished NCT06490367 record still lists
NCT06490367 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 635-participant average among 35 other Huntington Disease trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Huntington Disease appearing as the primary indexed condition, and to 1 intervention - of which Time-Restricted Eating Diet is the first listed.
NCT06490367 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT06490367 about?
NCT06490367 is a clinical study titled "Time-Restricted Eating in Huntington's Disease: A Clinical Pilot Study". This trial examines whether 12 weeks of time-restricted eating (TRE), otherwise known as intermittent fasting, appears safe and feasible in persons with early-stage Huntington's disease (HD). The study also explores the effects of TRE on biomarkers and clinical measures associated with HD progressio...
What is the current status of trial NCT06490367?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. The study started on 2024-08-29. Estimated completion is 2025-05-30.
What conditions does trial NCT06490367 study?
This clinical trial studies the following conditions: Huntington Disease.
What interventions are being tested in trial NCT06490367?
The interventions under investigation include: Time-Restricted Eating Diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT06490367?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06490367 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Huntington Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06490367's enrollment target sits among peer trials
22 28th of 35 higher than 8 of 35 other Huntington Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Huntington Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3)
RECRUITING · NA
-
Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease
RECRUITING · NA
-
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
RECRUITING · NA
-
Home-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease
RECRUITING · NA
-
Move to Improve: Telehealth Exercise to Music for HD
COMPLETED · NA
-
Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI